Trend in approval of targeted biologics in the last two decades
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
| Egile nagusia: | Siddika, Khadiza |
|---|---|
| Beste egile batzuk: | Ahmed, Syeda Maliha |
| Formatua: | Thesis |
| Hizkuntza: | English |
| Argitaratua: |
Brac University
2024
|
| Gaiak: | |
| Sarrera elektronikoa: | http://hdl.handle.net/10361/24296 |
Antzeko izenburuak
-
Targeted therapeutic options in the treatment of Breast Cancer
nork: Alam, Kazi Tasnuva
Argitaratua: (2022) -
Study on anticancer drugs approved by the FDA from 2014 to 2023
nork: Rattry, Faria Rahman
Argitaratua: (2024) -
Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars
nork: Tania, Umme
Argitaratua: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
nork: Jahan, Nusrat
Argitaratua: (2024) -
SIRT6 and cancer stem cells: is there any implication?
nork: Sarker, Tanosi
Argitaratua: (2022)